Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab

NCT04013854 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT04013854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04013854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 1, 2020
Completion date
December 24, 2027
Enrollment
67 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma stage iii